Remestemcel
| Clinical data | |
|---|---|
| Trade names | Ryoncil |
| Other names | JR-0301, remestemcel-L-rknd, remestemcel-L (USAN US) |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
Remestemcel, sold under the brand name Ryoncil, is an allogeneic bone marrow-derived mesenchymal stromal cell therapy used for the treatment of graft-versus-host disease.[1][2]
Remestemcel was approved for medical use in the United States in December 2024.[1][2]
Medical uses
Remestemcel is indicated for the treatment of steroid-refractory acute graft-versus-host disease.[1][2]
Society and culture
Legal status
Remestemcel was approved for medical use in the United States in December 2024.[2][3]
Names
Remestemcel is the international nonproprietary name.[4]
Remestemcel-L is the United States Adopted Name.[5]
References
- ^ a b c d https://www.fda.gov/media/184603/download
- ^ a b c d e "Ryoncil". U.S. Food and Drug Administration. 1 October 2024. Retrieved 20 December 2024.
- ^ "Mesoblast's Ryoncil is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy" (Press release). Mesoblast. 19 December 2024. Retrieved 20 December 2024 – via GlobeNewswire.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
- ^ "Remestemcel-L". AMA Finder. Retrieved 20 December 2024.
Further reading
- Mannon PJ (September 2011). "Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease". Expert Opinion on Biological Therapy. 11 (9): 1249–56. doi:10.1517/14712598.2011.602967. PMID 21787241.
External links
- "Remestemcel-L (Code C67082)". NCI Thesaurus.</ref>
- Clinical trial number NCT02336230 for "A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |